Evan Birkhead

2
Aug

AUG 2, 2017: UCLA study provides roadmap to more personalized treatment for soft tissue sarcoma and other aggressive cancers

PDOX has long shown great promise in modeling how sarcoma and other cancers can respond to and resist therapies. A new UCLA study, published in JCO Precision Oncology, is the first to identify patient and tumor characteristics that predict the successful creation of PDOX models and which types of sarcomas are most likely to grow as xenografts. The research, which

Read more

2
Aug

AUG 2, 2017: Certis Oncology: A Patient’s Story

Rachel — a wife, mother of two, and career woman — chats candidly about her oncology journey at UCLA: “If I didn’t have these mice, I wouldn’t know which drugs work on me.”

18
May

MAY 18, 2017: A strategic weapon in the fight against recalcitrant cancers.

According to the American Cancer Society’s Cancer Facts & Figures 2017,  there will be an estimated 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the US this year. This is horrible news that can’t be sugar coated.  Everyone’s life has been impacted by cancer and will continue to be. But if we take a peek at the micro-trends,

Read more

13
May

UCLA’S DR. FRITZ EILBER DISCUSSES HIS WORK WITH SARCOMA PATIENTS AND HIGHLIGHTS THE URGENCY OF FINDING THE RIGHT TREATMENT FOR EACH PATIENT.

Two landmark studies are now underway to determine if treatment can benefit the patient after only one cycle. Watch Here

18
Mar

MARCH 18, 2017: SSO 2017 ANNUAL CANCER SYMPOSIUM/SEATTLE

Session #70: Tumor Grade & Preoperative Therapy Impact the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts (PDOX): UCLA Sarcoma Program Prospective Clinical Trial By Dr. Tara Russell, M.D. Research Fellow/Surgical Resident UCLA Department of Surgical Oncology-1:30 p.m., Room 6A Abstract [pdf] | Given the diverse and often aggressive nature of soft tissue sarcomas (STS), there is a need for more

Read more

9
Mar

MARCH 9, 2017: CANCER FORUM/MUSCULOSKELETAL RESEARCH GROUP TUMOR BOARD PRESENTATION AT UCLA

Cancer Forum/Musculoskeletal Research Group Tumor Board presentation at UCLA     “Tumor Grade & Neoadjuvant Therapy Impact The Establishment of Soft-Tissue Sarcoma Patient-Derived Orthotopic Xenografts (PDOX): A UCLA Sarcoma Program Prospective Clinical Trial” By Tara Russell, M.D. Research Follow/Surgical Resident UCLA Department of Surgical Oncology 3:30 p.m., SM UCLA Conference Room #3 Objective: Feasibility of Personalized Oncology Care in Sarcoma

Read more

9
Nov

NOVEMBER 9, 2016: CONNECTIVE TISSUE ONCOLOGY SOCIETY (CTOS), LISBON, PORTUGAL

“Factors Impacting the Establishment of Individual Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts (PDOX) Mouse Models: A UCLA Sarcoma Program Prospective Clinical Trial” by Eckardt et al. By Tara Russell, MD, MPH UCLA General Surgery Resident This study demonstrates a very high (82%) establishment rate for PDOX in HG-STS patients who were treatment naïve at the time of surgical excision. Learn

Read more